Oppenheimer Initiates Coverage On Ambrx Biopharma with Outperform Rating, Announces Price Target of $30
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Matthew Biegler initiates coverage on Ambrx Biopharma (NASDAQ:AMAM) with an Outperform rating and announces a price target of $30.
June 02, 2023 | 8:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer initiates coverage on Ambrx Biopharma with an Outperform rating and a price target of $30.
The initiation of coverage by Oppenheimer with an Outperform rating and a price target of $30 indicates a positive outlook for Ambrx Biopharma. This news is likely to have a positive short-term impact on the stock price as it reflects the analyst's confidence in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100